Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ Jr, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B. Williams CB, et al. Among authors: williams ka. Onco Targets Ther. 2015 Dec 1;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015. Onco Targets Ther. 2015. PMID: 26664139 Free PMC article.
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B. Willis S, et al. Among authors: williams c. PLoS One. 2016 Feb 17;11(2):e0149183. doi: 10.1371/journal.pone.0149183. eCollection 2016. PLoS One. 2016. PMID: 26886260 Free PMC article.
Mutation matters in precision medicine: A future to believe in.
Dey N, Williams C, Leyland-Jones B, De P. Dey N, et al. Among authors: williams c. Cancer Treat Rev. 2017 Apr;55:136-149. doi: 10.1016/j.ctrv.2017.03.002. Epub 2017 Mar 16. Cancer Treat Rev. 2017. PMID: 28371665 Review.
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M. Meißner T, et al. Among authors: williams c. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4):a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul. Cold Spring Harb Mol Case Stud. 2017. PMID: 28679691 Free PMC article.
11,224 results
You have reached the last available page of results. Please see the User Guide for more information.